Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Reiner-Link

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Bioorganic & Medicinal Chemistry|October 25, 2021
Histamine H<sub>3</sub> receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisationMarkus Falkenstein, David Reiner-Link, Aleksandra Zivkovic, et al.
British Journal of Pharmacology|May 10, 2024
Differential G protein activation by the long and short isoforms of the dopamine D<sub>2</sub> receptorDavid Reiner-Link, Jakob Sture Madsen, David E Gloriam, et al.
Molecules (Basel, Switzerland)|April 30, 2021
Discovery of Potential, Dual-Active Histamine H<sub>3</sub> Receptor Ligands with Combined Antioxidant PropertiesKamil J Kuder, Magdalena Kotańska, Katarzyna Szczepańska, et al.
Neuropharmacology|June 24, 2022
OLHA (N<sup>α</sup>-oleoylhistamine) modulates activity of mouse brain histaminergic neuronsOlga A Sergeeva, Karolina Mazur, David Reiner-Link, et al.
International Journal of Molecular Sciences|March 6, 2021
The Multi-Targeting Ligand ST-2223 with Histamine H<sub>3</sub> Receptor and Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Antagonist Properties Mitigates Autism-Like Repetitive Behaviors and Brain Oxidative Stress in MiceNermin Eissa, Karthikkumar Venkatachalam, Petrilla Jayaprakash, et al.
Bioorganic & Medicinal Chemistry|December 21, 2022
Multitargeting approaches to cognitive impairment: Synthesis of aryl-alkylpiperazines and assessment at cholinesterases, histamine H<sub>3</sub> and dopamine D<sub>3</sub> receptorsCecília M S Q Aranha, David Reiner-Link, Luisa R Leitzbach, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 25, 2024
Histamine H<sub>3</sub> receptor antagonist/nitric oxide donors as novel promising therapeutic hybrid-tools for glaucoma and retinal neuroprotectionSilvia Sgambellone, Mohammad A Khanfar, Silvia Marri, et al.
Critical Reviews in Clinical Laboratory Sciences|August 9, 2024
G protein-coupled receptor (GPCR) pharmacogenomicsMiles D Thompson, David Reiner-Link, Alessandro Berghella, et al.
European Journal of Pharmacology|October 5, 2020
Eosinophils adhesion assay as a tool for phenotypic drug screening - The pharmacology of 1,3,5 - Triazine and 1H-indole like derivatives against the human histamine H<sub>4</sub> receptorMarek Grosicki, Maristella Adami, Cristina Micheloni, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|February 15, 2023
Novel benzothiazole derivatives as multitargeted-directed ligands for the treatment of Alzheimer's diseaseDonia E Hafez, Mariam Dubiel, Gabriella La Spada, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Bioorganic & Medicinal Chemistry|October 25, 2021
Histamine H<sub>3</sub> receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisationMarkus Falkenstein, David Reiner-Link, Aleksandra Zivkovic, et al.
British Journal of Pharmacology|May 10, 2024
Differential G protein activation by the long and short isoforms of the dopamine D<sub>2</sub> receptorDavid Reiner-Link, Jakob Sture Madsen, David E Gloriam, et al.
Molecules (Basel, Switzerland)|April 30, 2021
Discovery of Potential, Dual-Active Histamine H<sub>3</sub> Receptor Ligands with Combined Antioxidant PropertiesKamil J Kuder, Magdalena Kotańska, Katarzyna Szczepańska, et al.
Neuropharmacology|June 24, 2022
OLHA (N<sup>α</sup>-oleoylhistamine) modulates activity of mouse brain histaminergic neuronsOlga A Sergeeva, Karolina Mazur, David Reiner-Link, et al.
International Journal of Molecular Sciences|March 6, 2021
The Multi-Targeting Ligand ST-2223 with Histamine H<sub>3</sub> Receptor and Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Antagonist Properties Mitigates Autism-Like Repetitive Behaviors and Brain Oxidative Stress in MiceNermin Eissa, Karthikkumar Venkatachalam, Petrilla Jayaprakash, et al.
Bioorganic & Medicinal Chemistry|December 21, 2022
Multitargeting approaches to cognitive impairment: Synthesis of aryl-alkylpiperazines and assessment at cholinesterases, histamine H<sub>3</sub> and dopamine D<sub>3</sub> receptorsCecília M S Q Aranha, David Reiner-Link, Luisa R Leitzbach, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 25, 2024
Histamine H<sub>3</sub> receptor antagonist/nitric oxide donors as novel promising therapeutic hybrid-tools for glaucoma and retinal neuroprotectionSilvia Sgambellone, Mohammad A Khanfar, Silvia Marri, et al.
Critical Reviews in Clinical Laboratory Sciences|August 9, 2024
G protein-coupled receptor (GPCR) pharmacogenomicsMiles D Thompson, David Reiner-Link, Alessandro Berghella, et al.
European Journal of Pharmacology|October 5, 2020
Eosinophils adhesion assay as a tool for phenotypic drug screening - The pharmacology of 1,3,5 - Triazine and 1H-indole like derivatives against the human histamine H<sub>4</sub> receptorMarek Grosicki, Maristella Adami, Cristina Micheloni, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|February 15, 2023
Novel benzothiazole derivatives as multitargeted-directed ligands for the treatment of Alzheimer's diseaseDonia E Hafez, Mariam Dubiel, Gabriella La Spada, et al.
Pageof 2